Sat Kartar Shopping Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 307 Cr.
- Current Price ₹ 195
- High / Low ₹ 242 / 130
- Stock P/E
- Book Value ₹
- Dividend Yield 0.36 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
1 November 2025 - Earnings concall audio for half-year ended Sep 30, 2025 uploaded on company website (01-Nov-2025).
-
General Updates
31 October 2025 - Exchange caution for delayed submission of May 19, 2025 post-earnings call audio; board noted, corrective measures initiated.
-
Updates
30 October 2025 - Investor presentation H1FY26 details acquisitions, in-house capsule facility commissioning, SECI partnership; targets ₹500 Cr by FY28.
-
Updates
30 October 2025 - H1FY26 presentation: acquired Ajooni and 76% Plantomed; Sat Kartar USA acquisition; in-house capsule facility commissioned; SECI partnership; ₹500Cr 2028 target.
-
Press Release
30 October 2025 - H1FY26 revenue ₹88.35Cr, PAT ₹7.79Cr (103.8%); launching Ayurvedic hospitals; earnings call Nov 1, 2025.
Annual reports
Concalls
-
Oct 2025TranscriptNotesPPT
-
Oct 2025TranscriptNotesPPT
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.